All articles tagged with #compounded drugs
Despite FDA efforts to curb the sale of cheap, off-brand GLP-1 weight loss drugs like Ozempic, these medications are still widely available through pharmacies exploiting legal loopholes, driven by high demand and high prices of brand-name drugs, highlighting ongoing issues in drug accessibility and regulation in the US.
Novo Nordisk has filed 14 lawsuits against vendors selling cheaper compounded versions of its obesity drug Wegovy (semaglutide), intensifying its legal efforts to protect its product.
Many Americans seeking to lose weight are turning to alternatives to Ozempic, a new "wonder drug" for obesity. Compounded semaglutide, the active ingredient in Ozempic, is being sought out due to cost and supply issues with brand name drugs. However, experts and officials have raised concerns about the possible risks of compounded weight loss drugs. The soaring demand for these medications, fueled by their effectiveness and celebrity endorsements, has led to shortages and restrictions. The US FDA warns that compounded drugs pose a higher risk to patients and has received adverse event reports related to compounded semaglutide. Despite the uncertainties, individuals like Marissa Montanino are experiencing weight loss success and intend to continue using the drugs.
The FDA is warning people to avoid compounded ketamine, which is being sold as a treatment for depression and other mental health issues without being tested or authorized for such uses. The agency has received reports of people being harmed by these products, which are often marketed and sold through telemedicine companies. Compounded ketamine can be taken without supervision and the dosages can vary widely, posing potential risks to individuals. While ketamine-based therapies show promise for mental health conditions, the FDA emphasizes that there is no evidence to suggest that compounded ketamine is safer or more effective than FDA-approved medications.
The FDA has issued a warning about the dangers of using compounded versions of ketamine for the treatment of psychiatric disorders. Compounded drugs are modified versions tailored to individual patients. The unsupervised use of compounded ketamine can lead to dangerous psychiatric reactions and health problems such as increased blood pressure, respiratory depression, and urinary tract issues. The FDA emphasized the importance of differentiating between supervised use of ketamine in clinics and wellness centers versus online marketers who prescribe the drug via telemedicine. The use of ketamine for psychiatric purposes, except for esketamine nasal spray, is unapproved and unregulated. The pandemic-related rise in telehealth has led to an increase in online prescribers dispensing ketamine, raising concerns about misuse and addiction. The FDA's alert did not include data on adverse reactions but cited a case of respiratory depression in a patient who took compounded oral ketamine outside of a healthcare setting.
The demand for weight loss drugs like Ozempic, Wegovy, and Mounjaro has surged, but many people face obstacles in accessing these medications due to prescription and insurance coverage issues. As a result, a niche industry of compounding pharmacies has emerged, offering knockoff versions of these drugs. However, the FDA has issued a warning about the potential dangers of compounded semaglutide, citing reports of unexpected health problems. Compounded drugs are not regulated by the FDA, raising concerns about their safety and efficacy. Experts caution against using these drugs due to the risks involved and the lack of nutritional counseling that typically accompanies legitimate weight loss medications.
The FDA has warned that compounded versions of semaglutide, a drug used for weight loss and diabetes treatment, could cause dangerous side effects. However, the high cost of name-brand options has led some patients to ignore the warning and turn to compounded versions. Compounding pharmacies are not regulated by the FDA, and the active ingredients in compounded semaglutide may not be FDA-approved. Despite the risks, many patients are turning to compounded versions due to the cost. Doctors warn that the potential harm of compounded semaglutide may not be worth the low cost.
The FDA has warned consumers against using off-brand versions of popular weight-loss drugs Ozempic, Rybelsus, and Wegovy, as they may contain different ingredients from the brand-name drugs that are neither safe nor effective. Compounded versions of the drug's active ingredient, semaglutide, have been reported to cause problems. Compounded drugs are not FDA-approved, and the agency does not verify their safety or effectiveness. Some states have raised concerns about the safety of some of the compounded drugs, and states have tried to take action to curb their manufacturing.